

Title (en)
ORAL LIPOSOMAL COMPOSITIONS

Title (de)
ORALE LIPOSOMALE ZUSAMMENSETZUNGEN

Title (fr)
COMPOSITIONS LIPOSOMALES ORALES

Publication
EP 4284332 A1 20231206 (FR)

Application
EP 22701404 A 20220128

Priority
• FR 2100892 A 20210129
• EP 2022052020 W 20220128

Abstract (en)
[origin: WO2022162131A1] The invention relates to a liposomal composition for oral, nasal or pulmonary administration, comprising a negatively charged phospholipid, optionally a zwitterionic phospholipid, a sterol, and one or more amphiphilic substances of biological interest, preferably a lipophilic immunostimulant useful for treating and/or preventing any pathology involving activation of monocytes and/or macrophages.

IPC 8 full level
A61K 9/00 (2006.01); **A61K 9/10** (2006.01); **A61K 9/127** (2006.01); **A61K 47/24** (2006.01)

CPC (source: EP US)
A61K 9/0053 (2013.01 - EP US); **A61K 9/10** (2013.01 - EP); **A61K 9/127** (2013.01 - EP US); **A61K 38/14** (2013.01 - US); **A61K 47/24** (2013.01 - EP US); **A61K 47/28** (2013.01 - US); **A61P 35/00** (2018.01 - US); **Y02A 50/30** (2018.01 - EP)

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

Designated validation state (EPC)
KH MA MD TN

DOCDB simple family (publication)
WO 2022162131 A1 20220804; AU 2022212571 A1 20230803; AU 2022212571 A9 20240516; CA 3204844 A1 20220804; CN 116981441 A 20231031; EP 4284332 A1 20231206; FR 3119325 A1 20220805; FR 3119325 B1 20230811; JP 2024504814 A 20240201; US 2024108685 A1 20240404

DOCDB simple family (application)
EP 2022052020 W 20220128; AU 2022212571 A 20220128; CA 3204844 A 20220128; CN 202280019481 A 20220128; EP 22701404 A 20220128; FR 2100892 A 20210129; JP 2023546165 A 20220128; US 202218263248 A 20220128